Pneumococcal 23-valent vaccine (Sinovac Biotech)

23价肺炎球菌多糖疫苗（ 科兴生物）

Report date: 2023/11/01 10:57:43

Base Information

Drug NamePneumococcal 23-valent vaccine (Sinovac Biotech)
Drug Alias Name23-valent PPV23-valent pneumococcal polysaccharide vaccine(Sinovac Biotech)PPV-23
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPneumonia, PneumococcalPneumococcal Infections
Global Approved IndicationsPneumococcal Infections
Approved Indications in ChinaPneumococcal Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinovac Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinovac Biotech Ltd
Inactive CompaniesSinovac Biotech Co LtdSinovac Life Sciences Co Ltd
Active IndicationsPneumococcal Infections
Inactive IndicationsPneumonia, Pneumococcal

Other Information

ATC CodeJ07AL01
Related LinksN/A